BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 11853669)

  • 1. Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1.
    Bernier-Villamor V; Sampson DA; Matunis MJ; Lima CD
    Cell; 2002 Feb; 108(3):345-56. PubMed ID: 11853669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of an N-terminal site of Ubc9 in SUMO-1, -2, and -3 binding and conjugation.
    Tatham MH; Kim S; Yu B; Jaffray E; Song J; Zheng J; Rodriguez MS; Hay RT; Chen Y
    Biochemistry; 2003 Aug; 42(33):9959-69. PubMed ID: 12924945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insights into E3 ligase activity revealed by a SUMO-RanGAP1-Ubc9-Nup358 complex.
    Reverter D; Lima CD
    Nature; 2005 Jun; 435(7042):687-92. PubMed ID: 15931224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of two residues proximal to the active site of Ubc9 in substrate recognition by the Ubc9.SUMO-1 thiolester complex.
    Tatham MH; Chen Y; Hay RT
    Biochemistry; 2003 Mar; 42(11):3168-79. PubMed ID: 12641448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ubc9p and the conjugation of SUMO-1 to RanGAP1 and RanBP2.
    Saitoh H; Sparrow DB; Shiomi T; Pu RT; Nishimoto T; Mohun TJ; Dasso M
    Curr Biol; 1998 Jan; 8(2):121-4. PubMed ID: 9427648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative allosteric mechanisms can regulate the substrate and E2 in SUMO conjugation.
    Karaca E; Tozluoğlu M; Nussinov R; Haliloğlu T
    J Mol Biol; 2011 Mar; 406(4):620-30. PubMed ID: 21216249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SUMO wrestling with specificity.
    VanDemark AP; Hill CP
    Structure; 2002 Mar; 10(3):281-2. PubMed ID: 12005425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a substrate recognition site on Ubc9.
    Lin D; Tatham MH; Yu B; Kim S; Hay RT; Chen Y
    J Biol Chem; 2002 Jun; 277(24):21740-8. PubMed ID: 11877416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of small ubiquitin-like modifier 1 (SUMO1) protein specificity, E3 ligase, and SUMO-RanGAP1 binding activities of nucleoporin RanBP2.
    Gareau JR; Reverter D; Lima CD
    J Biol Chem; 2012 Feb; 287(7):4740-51. PubMed ID: 22194619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modification of Ran GTPase-activating protein by the small ubiquitin-related modifier SUMO-1 requires Ubc9, an E2-type ubiquitin-conjugating enzyme homologue.
    Lee GW; Melchior F; Matunis MJ; Mahajan R; Tian Q; Anderson P
    J Biol Chem; 1998 Mar; 273(11):6503-7. PubMed ID: 9497385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purification and activity assays for Ubc9, the ubiquitin-conjugating enzyme for the small ubiquitin-like modifier SUMO.
    Yunus AA; Lima CD
    Methods Enzymol; 2005; 398():74-87. PubMed ID: 16275321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure of ubiquitin-conjugating enzyme 9 displays significant differences with other ubiquitin-conjugating enzymes which may reflect its specificity for sumo rather than ubiquitin.
    Giraud MF; Desterro JM; Naismith JH
    Acta Crystallogr D Biol Crystallogr; 1998 Sep; 54(Pt 5):891-8. PubMed ID: 9757105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The RanBP2/RanGAP1*SUMO1/Ubc9 complex is a multisubunit SUMO E3 ligase.
    Werner A; Flotho A; Melchior F
    Mol Cell; 2012 May; 46(3):287-98. PubMed ID: 22464730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ubiquitin-like proteins SMT3 and SUMO-1 are conjugated by the UBC9 E2 enzyme.
    Schwarz SE; Matuschewski K; Liakopoulos D; Scheffner M; Jentsch S
    Proc Natl Acad Sci U S A; 1998 Jan; 95(2):560-4. PubMed ID: 9435231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysine activation and functional analysis of E2-mediated conjugation in the SUMO pathway.
    Yunus AA; Lima CD
    Nat Struct Mol Biol; 2006 Jun; 13(6):491-9. PubMed ID: 16732283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The RanBP2/RanGAP1*SUMO1/Ubc9 SUMO E3 ligase is a disassembly machine for Crm1-dependent nuclear export complexes.
    Ritterhoff T; Das H; Hofhaus G; Schröder RR; Flotho A; Melchior F
    Nat Commun; 2016 May; 7():11482. PubMed ID: 27160050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SUMO modification through rapamycin-mediated heterodimerization reveals a dual role for Ubc9 in targeting RanGAP1 to nuclear pore complexes.
    Zhu S; Zhang H; Matunis MJ
    Exp Cell Res; 2006 Apr; 312(7):1042-9. PubMed ID: 16469311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E2-mediated small ubiquitin-like modifier (SUMO) modification of thymine DNA glycosylase is efficient but not selective for the enzyme-product complex.
    Coey CT; Fitzgerald ME; Maiti A; Reiter KH; Guzzo CM; Matunis MJ; Drohat AC
    J Biol Chem; 2014 May; 289(22):15810-9. PubMed ID: 24753249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural and dynamic independence of isopeptide-linked RanGAP1 and SUMO-1.
    Macauley MS; Errington WJ; Okon M; Schärpf M; Mackereth CD; Schulman BA; McIntosh LP
    J Biol Chem; 2004 Nov; 279(47):49131-7. PubMed ID: 15355965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The small ubiquitin-like modifier-1 (SUMO-1) consensus sequence mediates Ubc9 binding and is essential for SUMO-1 modification.
    Sampson DA; Wang M; Matunis MJ
    J Biol Chem; 2001 Jun; 276(24):21664-9. PubMed ID: 11259410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.